证券日报网讯新和成11月24日发布公告，在公司回答调研者提问时表示，公司致力于成为新材料行业的 生力军，重点发展高性能聚合物及关键中间体，适度发展材料下游应用，目前主要产品包括聚苯硫醚 （PPS）、高温尼龙（PPA）、IPDA、HDI、IPDI等，产品性能和品质可以达到国际先进水平。PPS具 有机械强度高、耐高温、耐化学药品性、热稳定性好、电性能优良、耐辐射和阻燃等优点，在新能源、 半导体、高端制造等领域的需求增长显著，公司PPS报批3万吨，公司PPS现有产能2.2万吨，后续公司 将结合公司战略规划和市场发展态势，稳步有序推进扩建产能项目建设。 （文章来源：证券日报） ...

证券代码：002001 证券简称：新和成 6、公司全氟己基辛烷项目进展情况？ 答：公司年产 45 吨全氟己基辛烷、15 吨全氟丁基戊烷项 目已具备生产能力，两款产品是治疗干眼症药物的重要原料药， 已取得药品注册。 7、公司草铵膦和精草铵膦的进展情况如何？ 4、公司在新材料板块的布局？公司对 PPS 业务有哪些发展 规划？ 答：公司致力于成为新材料行业的生力军，重点发展高性能 聚合物及关键中间体，适度发展材料下游应用，目前主要产品包 括聚苯硫醚（PPS）、高温尼龙（PPA）、IPDA、HDI、IPDI 等， 产品性能和品质可以达到国际先进水平。PPS 具有机械强度高、 耐高温、耐化学药品性、热稳定性好、电性能优良、耐辐射和阻 燃等优点，在新能源、半导体、高端制造等领域的需求增长显著， 公司 PPS 报批 3 万吨，公司 PPS 现有产能 2.2 万吨，后续公司将 结合公司战略规划和市场发展态势，稳步有序推进扩建产能项目 建设。 5、公司香料板块主要有哪些产品，增长动力在哪里？ 答：目前公司香精香料板块主要生产芳樟醇系列、柠檬醛系 列、叶醇系列、二氢茉莉酮酸甲酯、薄荷醇等多种香料，被广泛 应用于个人护理、家庭护理 ...

Core Viewpoint - The article discusses the recent advancements in the production of bio-based polyphenylene sulfide (PPS) by Zhejiang Xinheng and the expansion of production capacity by Toray Advanced Materials in South Korea, highlighting the growing market for PPS and its applications in various industries [2][3]. Group 1: Company Developments - Zhejiang Xinheng has successfully launched bio-based PPS products with 100% bio-based content, matching the mechanical performance of traditional products, and has entered the small-scale sales phase [2]. - The total planned production capacity for Xinheng's PPS is 30,000 tons, with 22,000 tons already built and a target utilization rate of 100% by 2024 [2]. - Toray Advanced Materials has completed the expansion of its PPS production line in Gunsan, South Korea, increasing its annual capacity to 13,600 tons [2]. Group 2: Market Landscape - The global PPS resin production capacity is concentrated in Northeast Asia and North America, with the top five producers accounting for 60% of the total capacity [3]. - As of June 2025, China has 250,000 tons of planned PPS projects under construction, with an expected total capacity of 129,000 tons by the end of 2025 [3]. - The domestic consumption of PPS is projected to be 56,000 tons in 2024, with approximately 30,000 tons relying on imports from international giants like Celanese and Toray, resulting in a self-sufficiency rate of only 46.4% [3]. Group 3: Industry Applications - PPS is recognized for its excellent high-temperature resistance, chemical corrosion resistance, flame retardancy, and dimensional stability, making it suitable for various applications [2][3]. - The largest demand for PPS is in the electric vehicle sector, where it is used in components such as explosion-proof battery covers and electronic pumps [7]. - Other significant applications include robotics, electronics, and aerospace, where PPS is utilized in lightweight structural components and circuit board substrates [7].

Core Viewpoint - The company, Xinhecheng (002001), has demonstrated steady growth in revenue and net profit, with a focus on innovation and expansion across its various business segments, including nutrition products, pharmaceuticals, and new materials [2][10]. Group 1: Company Overview - The company operates two main platforms: "Chemicals+" and "Biology+", with significant potential for growth in both areas [2]. - The research and development system is structured around three levels: science, technology, and application, emphasizing the importance of scientific discovery in driving technological advancements [2]. - For the first three quarters of 2025, the company reported a total revenue of 16.642 billion yuan, a year-on-year increase of 5.45%, and a net profit attributable to shareholders of 5.321 billion yuan, up 33.37% [2][10]. Group 2: Nutrition Products - The nutrition segment is the largest business area, encompassing both animal and human nutrition products, including a variety of vitamins and amino acids [2]. - Key products in the human nutrition category include Vitamin D3, Vitamin E, Vitamin C, Coenzyme Q10, and others, with a focus on expanding applications in the food and beverage sectors [2]. Group 3: Methionine Production - The company has a current production capacity of 300,000 tons for solid methionine, with an expansion project of 70,000 tons approved and progressing well [3]. - A joint venture with Sinopec for a liquid methionine project is also in the process of resuming production, indicating a strong outlook for methionine demand driven by global population growth and health awareness [3]. Group 4: Biochemical Fermentation - The company is optimistic about the future of its biochemical fermentation segment, which includes products like Vitamin C and various amino acids [4]. - Plans are in place to expand into new products within the fermentation category, targeting applications in nutrition, amino acids, and potentially new materials [4]. Group 5: Pharmaceutical Raw Materials - The pharmaceutical raw materials segment focuses on high-quality vitamin series and other active pharmaceutical ingredients, providing essential services to pharmaceutical companies [5]. - The company has successfully registered and industrialized a new eye drop formulation, showcasing its commitment to innovation in the pharmaceutical sector [5]. Group 6: New Materials - The company aims to become a key player in the new materials industry, focusing on high-performance polymers and critical intermediates [6]. - The new materials segment is expected to benefit from significant market demand in sectors such as renewable energy, semiconductors, and advanced manufacturing [6]. Group 7: Capital Expenditure and Future Projects - The company is actively pursuing capital expenditures for new product launches and ongoing projects, including a nylon new materials project in Tianjin [10]. - Future capital expenditures will be aligned with market conditions and specific project developments, indicating a strategic approach to growth [10]. Group 8: Financial Performance - In Q3 2025, the company reported a single-quarter revenue of 5.541 billion yuan, a decrease of 6.66% year-on-year, and a net profit of 1.717 billion yuan, down 3.8% [10]. - The overall financial health is reflected in a debt ratio of 28.25% and a gross profit margin of 45.55% [10].

Core Viewpoint - Zhejiang Xinhengcheng Co., Ltd. (hereinafter referred to as "Xinhengcheng") has demonstrated robust growth in its financial performance, with a focus on expanding its business segments and future development plans through a synergistic approach in its "Chemical+" and "Biological+" platforms [2][3]. Group 1: Financial Performance - For the first three quarters of 2025, Xinhengcheng achieved a revenue of 16.642 billion yuan, representing a year-on-year increase of 5.45% [2]. - The net profit attributable to shareholders reached 5.321 billion yuan, marking a significant year-on-year growth of 33.37% [2]. Group 2: Business Segments - The nutrition segment is currently the largest business area, encompassing both animal and human nutrition products, including vitamins and amino acids, with a steady annual revenue growth [2]. - In the human nutrition sector, products include vitamins A, D3, E, C, coenzyme Q10, taurine, and β-carotene, with a continuous expansion of customized formulations [2]. Group 3: Production Capacity and Expansion - The company currently has a solid methionine production capacity of 300,000 tons, with a 70,000-ton expansion project approved and set to be launched based on market conditions [3]. - An 180,000-ton/year liquid methionine project, in partnership with Sinopec, is progressing towards resumption after maintenance [3]. Group 4: Future Development and Projects - The biological fermentation segment is expected to expand into flavors and new materials, while the raw materials pharmaceutical segment focuses on pharmaceutical-grade vitamins and other key products [3]. - The new materials segment is identified as a future pillar industry, emphasizing the development of high-performance polymers and key intermediates, with ongoing construction of a nylon new materials project [5]. - The company plans to advance new products like serine and tryptophan, while also reserving land for flavor projects and dynamically adjusting capital expenditures based on project progress [6].

Group 1: Company Overview - Zhejiang Xinhengcheng Co., Ltd. operates two major platforms: "Chemicals+" and "Biology+" with significant growth potential in both areas [2][3] - The company focuses on a robust R&D system that integrates scientific discovery, technology, and application to enhance product effectiveness [3] Group 2: Financial Performance - In the first three quarters of 2025, the company achieved a total revenue of CNY 16.642 billion, representing a year-on-year growth of 5.45% [3] - The net profit attributable to shareholders reached CNY 5.321 billion, marking a substantial increase of 33.37% compared to the previous year [3] Group 3: Nutritional Products - The nutrition segment is the largest business area, encompassing animal and human nutrition products, including a variety of vitamins and amino acids [3][4] - Key human nutrition products include Vitamin A, D3, E, C, Coenzyme Q10, Taurine, β-Carotene, and Lycopene, with a diverse range of formulations [3] Group 4: Methionine Production - The company has a solid methionine production capacity of 300,000 tons, with an additional 70,000 tons expansion project approved and progressing well [4] - A joint venture with Sinopec for a 180,000 tons/year liquid methionine project is currently undergoing maintenance before resuming production [4] Group 5: Biochemical Fermentation - The company is optimistic about the future of its biochemical fermentation segment, focusing on products like Vitamin C and Coenzyme Q10 [5] - Plans to expand into new products in the fermentation category, including amino acids and new materials, are underway [5] Group 6: Active Pharmaceutical Ingredients - The company specializes in pharmaceutical-grade vitamins and other active pharmaceutical ingredients, providing high-quality raw materials and services to pharmaceutical companies [5] - The company has developed a water-free eye drop formulation that has achieved industry-leading status in treatment efficacy and side effect management [5] Group 7: New Materials Development - The company aims to become a key player in the new materials sector, focusing on high-performance polymers and critical intermediates [5] - The Tianjin nylon new materials project is progressing, with construction initiated in September 2025 [5][6] Group 8: Future Capital Expenditure - Future capital expenditures will be aligned with specific project developments, including the expansion of the PPS project and the establishment of a new flavoring project [6]

Financial Performance - In Q3 2025, the company achieved a revenue of 166.42 billion CNY, with a net profit attributable to shareholders of 55.41 billion CNY, reflecting a year-on-year revenue growth of 5.45% and a net profit increase of 33.37% [3] - The company has maintained steady growth through production and sales linkage, market expansion, and cost control measures [3] Product Development and Market Strategy - The company focuses on the "Chemical+" and "Biological+" strategies, targeting opportunities in nutrition products, new materials, flavoring agents, and active pharmaceutical ingredients [3] - In the human nutrition sector, the company offers a range of products including vitamins A, D3, E, C, coenzyme Q10, taurine, β-carotene, and lycopene, with a commitment to customized formulations for various applications [3] - The solid methionine production capacity is currently at 30,000 tons, with an expansion project underway [3] Strategic Partnerships and Projects - The company has partnered with Sinopec to establish a joint venture for a liquid methionine project, with a production capacity of 18,000 tons/year [3] - The nylon new materials project in Tianjin has commenced construction, focusing on an integrated production chain from adiponitrile to nylon 66 [4] Future Plans and Innovations - The company aims to enhance its core competitiveness in the new materials sector by developing high-performance polymers and key intermediates [4] - The company is expanding its flavor and fragrance segment, with plans for a new fragrance industrial park in Shandong [4] - The Heilongjiang base is focused on bio-fermentation products, with ongoing improvements in product lines and operational efficiency [4] International Expansion - Over 50% of the company's sales are from international markets, with established subsidiaries in regions including Hong Kong, Singapore, Germany, Mexico, Brazil, Japan, and Vietnam [6] - The company emphasizes overseas market expansion as part of its 2025 operational strategy [6] Employee Engagement and Incentives - The company is implementing a share buyback program with a total amount between 30 million to 360 million CNY, aimed at employee stock ownership plans to enhance motivation and align interests [6]

Core Viewpoint - Taihe Technology (300801.SZ) is advancing its product applications in robotics with its PEEK, PEN, and PPS materials, indicating a focus on innovation and potential market expansion [1] Group 1: Product Development - The PEEK project has completed the pilot test phase, suggesting readiness for further development [1] - The PEN and PPS projects are currently in the pilot testing stage and have not yet reached mass production, indicating ongoing research and development efforts [1] Group 2: Market Application - The products PEEK, PEN, and PPS are positioned for use in robotics-related applications, highlighting the company's strategic direction towards high-tech industries [1]

Group 1 - The company aims to become a key player in the new materials industry, focusing on high-performance polymers and key intermediates, while moderately developing downstream applications [1] - Main products include polyphenylene sulfide (PPS), high-temperature nylon (PPA), HDI, IPDA, and ADI, with a broad market outlook [1] - The PPS resin series can be used for both civilian and industrial yarns, achieving performance and quality that meet international advanced standards [1] Group 2 - The company has been questioned about its reserves in PA66 modification technology and its capability to produce industrial and civilian yarns [3] - There is a specific interest in whether the company's product performance and quality can match Invista's high-end products, particularly in terms of consistency, long-term reliability, stability under extreme conditions, special functional modifications, and applications in critical safety components [3] - Inquiry also extends to the company's technological reserves in new materials such as PEEK [3]

Core Viewpoint - The company is focused on developing high-performance polymers and key intermediates, aiming to become a significant player in the new materials industry, with a broad market outlook for its products [1]. Group 1: Company Strategy and Product Development - The company is committed to the "Chemicals +, Biology +" strategy, emphasizing the development of high-performance polymers and key intermediates [1]. - Current main products include polyphenylene sulfide (PPS), high-temperature nylon (PPA), HDI, IPDA, and ADI, which have a wide market potential [1]. Group 2: Product Capabilities and Market Position - The PPS resin series can be utilized for both industrial and civilian yarns, with product performance and quality meeting international advanced standards [1]. - The company is exploring its capabilities in PA66 modification technology and new materials like PEEK, indicating a focus on high-end product performance consistency and reliability under extreme conditions [1].